Tender Details
Description / Scope of Work
Jinnah Postgraduate Medical Centre, Karachi, a government institution under the Health Department of the Government of Sindh, is undertaking procurement of Evrysdi (Risdiplam) oral solution 60mg/80ml for the treatment of spinal muscular atrophy (SMA) in registered patients during the financial year 2026-2027. The procurement will be executed at the Karachi facility and involves acquisition of pharmaceutical stock for treating eligible SMA patients. The total tender value is approximately PKR 1,312,434 for the commercial quantity, with FOC (free of cost) provision valued at PKR 3,937,302 through Roche Pakistan as the sole authorized distributor. This is a direct contracting procurement processed under Clause 16(1)(b)(ii) of SPPRA rules 2010 due to the proprietary nature of the medication and availability through sole distributor channels.
Eligibility is typically restricted to authorized pharmaceutical distributors and suppliers registered with the relevant regulatory authorities. Bidders must be duly authorized representatives or distributors of Roche Pakistan Limited, the manufacturer and sole distributor of Evrysdi. Standard registration requirements with the Pakistan Medical and Dental Council (PMDC), National Tax Number (NTN), and Sales Tax registration are typically mandated. The procurement documentation must comply with SPPRA transparency requirements and all bidders must meet procurement compliance standards.
The procurement documents are to be uploaded on the EPAD (eProcurement and Auction Dashboard) system as requested by SPPRA to ensure full transparency and regulatory compliance. Interested parties should obtain detailed bid documents from the issuing authority and submit responses in accordance with SPPRA procurement rules. The financial year 2026-2027 timeline applies, with document submission and opening procedures to be conducted through official EPAD channels. Inquiries should be directed to the Executive Director, Jinnah Postgraduate Medical Centre, Karachi.
For Bidders: Our Analysis PAKISTANTENDER INSIGHT
Independent analysis by PakistanTender, written with AI from the official notice and checked by our quality rules — not part of the official notice. Always confirm details against the original tender document.
Direct contracting procurement for a proprietary pharmaceutical — Evrysdi oral solution for SMA treatment at a major government medical centre in Karachi.
Tender value approximately PKR 1.3 million commercial plus PKR 3.9 million FOC component. Sole distributor restriction (Roche Pakistan) significantly narrows competition. Typical for government-funded rare-disease therapies with restricted distribution. One-off procurement for FY 2026-27 patient cohorts; recurring annually likely if SMA patient census continues.
Who can bid: Must be authorized distributor of Roche Pakistan Limited. Typically requires NTN, Sales Tax registration, PMDC compliance, and direct appointment/authorization from manufacturer. Sole distributor model means eligibility is effectively limited to Roche's designated channel partners in Pakistan.